S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-2.14%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-2.14%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-2.14%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-2.14%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:NVAX - Novavax Stock Price, Forecast & News

$14.30
+1.25 (+9.58 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$12.87
Now: $14.30
$14.47
50-Day Range
$6.31
MA: $9.72
$16.00
52-Week Range
$3.54
Now: $14.30
$17.71
Volume6.44 million shs
Average Volume9.55 million shs
Market Capitalization$736.88 million
P/E RatioN/A
Dividend YieldN/A
Beta0.38
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as allows immunization with much lower doses of antigen. The company also develops RSV F vaccine for older adults in Phase II clinical trial, and healthy children between two and six years of age in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus in Phase I clinical trial, as well as MERS coronavirus in animals; and combination respiratory vaccine to protect against influenza and RSV. The company has a clinical development agreement with Bill & Melinda Gates Foundation. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Read More
Novavax logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NVAX
CUSIP67000210
Phone240-268-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.66 million
Book Value($5.75) per share

Profitability

Net Income$-132,690,000.00
Net Margins-711.04%

Miscellaneous

Employees373
Market Cap$736.88 million
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.


Novavax (NASDAQ:NVAX) Frequently Asked Questions

How has Novavax's stock been impacted by COVID-19 (Coronavirus)?

Novavax's stock was trading at $10.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVAX shares have increased by 36.1% and is now trading at $14.30. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Novavax?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novavax.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Novavax.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings data on Wednesday, March, 11th. The biopharmaceutical company reported ($1.13) EPS for the quarter, missing the Zacks' consensus estimate of ($1.06) by $0.07. The biopharmaceutical company earned $8.82 million during the quarter, compared to the consensus estimate of $3.99 million. View Novavax's earnings history.

When did Novavax's stock split? How did Novavax's stock split work?

Shares of Novavax reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for NVAX?

7 brokers have issued twelve-month price objectives for Novavax's stock. Their forecasts range from $7.00 to $24.00. On average, they anticipate Novavax's share price to reach $18.86 in the next year. This suggests a possible upside of 31.9% from the stock's current price. View analysts' price targets for Novavax.

Has Novavax been receiving favorable news coverage?

Media headlines about NVAX stock have been trending very positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novavax earned a news impact score of 4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutNovavax.

Who are some of Novavax's key competitors?

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Egalet (EGLT), EXACT Sciences (EXAS), Palo Alto Networks (PANW), Akebia Therapeutics (AKBA), TG Therapeutics (TGTX), Cara Therapeutics (CARA), Gilead Sciences (GILD), Trevena (TRVN), Opko Health (OPK) and Inovio Pharmaceuticals (INO).

Who are Novavax's key executives?

Novavax's management team includes the following people:
  • Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)
  • Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)
  • Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)
  • Dr. Gregory M. Glenn, Pres of R&D (Age 65)
  • Ms. Erika S. Trahan, Sr. Mang. of Investor & PR

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (1.33%), Charles Schwab Investment Management Inc. (0.46%), Bank of New York Mellon Corp (0.40%), TSP Capital Management Group LLC (0.39%), Nuveen Asset Management LLC (0.26%) and Ladenburg Thalmann Financial Services Inc. (0.14%). Company insiders that own Novavax stock include Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck. View institutional ownership trends for Novavax.

Which institutional investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including Creative Planning, Bank of America Corp DE, Nuveen Asset Management LLC, Virtu Financial LLC, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Sargent Investment Group LLC, and Sargent Investment Group LLC. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn, John A Herrmann III, John Trizzino, and Michael A Mcmanus Jr. View insider buying and selling activity for Novavax.

Which institutional investors are buying Novavax stock?

NVAX stock was acquired by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, Ikarian Capital LLC, UBS Group AG, Raymond James & Associates, Ladenburg Thalmann Financial Services Inc., Charles Schwab Investment Management Inc., Barclays PLC, and State Street Corp. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, John Trizzino, Rachel K King, and Stanley C Erck. View insider buying and selling activity for Novavax.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $14.30.

How big of a company is Novavax?

Novavax has a market capitalization of $736.88 million and generates $18.66 million in revenue each year. The biopharmaceutical company earns $-132,690,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Novavax employs 373 workers across the globe. View additional information about Novavax.

What is Novavax's official website?

The official website for Novavax is http://www.novavax.com/.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]


MarketBeat Community Rating for Novavax (NASDAQ NVAX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  763 (Vote Outperform)
Underperform Votes:  463 (Vote Underperform)
Total Votes:  1,226
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel